Evidence map›Paper›PMID 27776509›Full record

ArticleMicrobial cell factories2016

Biofilm as a production platform for heterologous production of rhamnolipids by the non-pathogenic strain Pseudomonas putida KT2440.

Vinoth Wigneswaran, Kristian Fog Nielsen, Claus Sternberg, Peter Ruhdal Jensen, Anders Folkesson, Lars Jelsbak

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Recent fermentation developments for improved rhamnolipid production.Applied microbiology and biotechnology · 2025
    Review
  3. EngineeringMolecules (Basel, Switzerland) · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. EngineeringMicrobiology spectrum · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Rheological Behavior of High Cell DensityBioengineering (Basel, Switzerland) · 2019
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Vinoth WigneswaranDepartment of Systems Biology, Technical University of Denmark, 2800, Kgs. Lyngby, Denmark.
Kristian Fog NielsenDepartment of Systems Biology, Technical University of Denmark, 2800, Kgs. Lyngby, Denmark.
Claus SternbergDepartment of Systems Biology, Technical University of Denmark, 2800, Kgs. Lyngby, Denmark.
Peter Ruhdal JensenNational Food Institute, Technical University of Denmark, 2800, Kgs. Lyngby, Denmark.
Anders FolkessonNational Veterinary Institute, Technical University of Denmark, 1870, Frederiksberg C, Denmark.
Lars JelsbakDepartment of Systems Biology, Technical University of Denmark, 2800, Kgs. Lyngby, Denmark. lj@bio.dtu.dk.ORCID http://orcid.org/0000-0002-5759-9769
Technical University of Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough a transition toward sustainable production of chemicals is needed, the physiochemical properties of certain biochemicals such as biosurfactants make them challenging to produce in conventional bioreactor systems. Alternative production platforms such as surface-attached biofilm populations could potentially overcome these challenges. Rhamnolipids are a group of biosurfactants highly relevant for industrial applications. However, they are mainly produced by the opportunistic pathogen Pseudomonas aeruginosa using hydrophobic substrates such as plant oils. As the biosynthesis is tightly regulated in P. aeruginosa a heterologous production of rhamnolipids in a safe organism can relive the production from many of these limitations and alternative substrates could be used.

resultsIn the present study, heterologous production of biosurfactants was investigated using rhamnolipids as the model compound in biofilm encased Pseudomonas putida KT2440. The rhlAB operon from P. aeruginosa was introduced into P. putida to produce mono-rhamnolipids. A synthetic promoter library was used in order to bypass the normal regulation of rhamnolipid synthesis and to provide varying expression levels of the rhlAB operon resulting in different levels of rhamnolipid production. Biosynthesis of rhamnolipids in P. putida decreased bacterial growth rate but stimulated biofilm formation by enhancing cell motility. Continuous rhamnolipid production in a biofilm was achieved using flow cell technology. Quantitative and structural investigations of the produced rhamnolipids were made by ultra performance liquid chromatography combined with high resolution mass spectrometry (HRMS) and tandem HRMS. The predominant rhamnolipid congener produced by the heterologous P. putida biofilm was mono-rhamnolipid with two C

conclusionThis study shows a successful application of synthetic promoter library in P. putida KT2440 and a heterologous biosynthesis of rhamnolipids in biofilm encased cells without hampering biofilm capabilities. These findings expands the possibilities of cultivation setups and paves the way for employing biofilm flow systems as production platforms for biochemicals, which as a consequence of physiochemical properties are troublesome to produce in conventional fermenter setups, or for production of compounds which are inhibitory or toxic to the production organisms.

Indexed as

BiofilmsGlycolipidsPseudomonas aeruginosaPseudomonas putidaGlycolipidsrhamnolipidBiofilmBiosurfactantsHeterologous biosynthesisPseudomonas putida KT2440RhamnolipidsSynthetic promoter libraryUHPLC-HRMSUHPLC-MS/HRMS

Identifiers

PMID27776509
PMCPMC5075983
OpenAlexW2534304485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.